| 영문 | medullary tumor | 한글 | 수질성 종양 |
|---|---|---|---|
| 설명 | 암의 병리학적인 분류중 하나. 여러 기관의 암에서 나타나는데 주로 갑상샘암이나 유방암에서 보인다. |
||
| 영문 | malignant tumor | 한글 | 악성종양 |
|---|---|---|---|
| 설명 | 정상적인 조직 세포가 각종 물리적-화학적-생물학적인 발암 물질의 작용 또는 요인에 의해 돌연변이를 일으켜서 형성되는 종양. 무제한의 세포분열로 매우 왕성하게 증식하여 주위조직을 파괴-침식한다. 또 어떤 화학물질을 내어 주위의 조직세포를 침해할 뿐만 아니라, 혈관 및 림프관을 따라 전이하여 전신의 카켁시아를일으켜 죽음을 초래한다. 상피성인 것을 암종이라 하고, 비상피성인 것을 육종이라 한다. |
||
| 영문 | benign tumor | 한글 | 양성종양 |
|---|---|---|---|
| 설명 | 발육속도가 완만하여 성장에 한계가 있고, 주위와의 경계가 명확하며, 다른 조직으로 퍼지지 않으며, 침윤이나 전이를 일으키지 아니하는 종양. 섬유종이나 지방종 따위가 전형적인 예이다. 양성종양은 종양이 존재한다고 해도 1차적으로 숙주의 생명을 위협하는 일은 없다. 양성종양의 발육형식은 주위의 조직간에 왕래하는 일이 없이 주위의 조직을 밀어내며 증식한다. 발육속도는 완만하며 전이하거나 절제 후 재발하는 일이 극히 드물다. 종양성분은 변이체이긴 하지만 성숙한 정상세포와 거의 다른 것이 없다. 전신에 대한 영향은 악성종양의 경우 어느 정도 발육했을 때 전신의 영양상태가 손상되어 카켁시아가 되지만 양성종양의 경우 이런 일은 거의 없다. 양성종양과 악성종양의 성상의 차이에 엄밀한 경계는 없고, 경계경변으로 보이는 종양도 있다. |
||
| 영문 | Wilms' tumor | 한글 | 윌름즈종양 |
|---|---|---|---|
| 설명 | 콩팥에서 발생하는 악성종양으로 소아에서 자주 발생한다. 흔히 소아에서 복부내종양을 발견시 중앙선을 넘어서면 신경모세포종이고, 중앙선을 넘지 않으면 윌름즈종양을 의심할 만큼 중요하고 흔한 종양이다. 대개 증상은 없는 편이며, 주로 아기의 목욕을 시켜주다가 우연히 발견된 복부내종괴 때문에 병원을 찾게 된다. 진단시 컴퓨터단층촬영으로 주위의 전이가 없는지를 확인해야 하며, 전이가 없으면 항암화학요법, 방사선치료요법, 그리고 수술요법의 병합요법에 의한 치료효과가 높다. |
||
| 영문 | mucinous tumor | 한글 | 점액종양 |
|---|---|---|---|
| 설명 | 점액으로 구성된 종양을 말하는데 주로 여성의 난소에서 발생하는 낭성(물주머니같은 종양을 말함) 종양에서 많이 볼 수 있다. |
||
| TP | temperature and pressure; temperature probe; temporal peak; temporoparietal; tension pneumothorax; t... |
|---|---|
| MAP | malignant atrophic papulosis; mandibular angle plane; maturation-activated protein; maximal aerobic ... |
| MBP | major basic protein; maltose-binding protein; management by policy; mannose-binding protein; mean bl... |
| RP | radial pulse; radiopharmaceutical; rapid processing [of film]; Raynaud phenomenon; reactive protein;... |
| TCP | T-complex protein; therapeutic continuous penicillin; total circulating protein; transcutaneous pace... |
| suppressor mutation | <molecular biology> Mutation that alleviates the effect of a primary mutation at a different locus. May be through almost any mechanism that can give a primary mutation, but perhaps the most interesting class are the amber and ochre supressors, where the anticodon of the tRNA is altered so that it mis reads the termination codon and inserts an amino acid, preventing premature termination of the peptide chain. (18 Nov 1997) |
|---|---|
| suppressor-sensitive mutant | A conditionally lethal, host range, bacteriophage mutant that produces nonsense codons and can replicate only in a host bacterium able to translate the nonsense codon; the mutation's effects are lethal (i.e., prevent replication of the virus) in a bacterium without such a suppressor mechanism. (05 Mar 2000) |
| suppressor T-cell | <immunology> See T-cells. (18 Nov 1997) |
| suppressor tRNA | The tRNA associated with a suppressor mutation. (05 Mar 2000) |
| ochre suppressor | A gene that codes for an altered tRNA so that its anticodon can recognise the ochre codon and thus allows the continuation of protein synthesis. A suppressor of an ochre mutation is a tRNA that is charged with the amino acid corresponding to the original codon or a neutral substitute. Ochre suppressors will also suppress amber codons. (18 Nov 1997) |
| opal suppressor | <molecular biology> A gene that codes for an altered tRNA so that its anticodon can recognise the opal codon and thus allows the continuation of protein synthesis. A suppressor of an opal mutation is a tRNA that is charged with the amino acid corresponding to the original codon or a neutral substitute. Some eukaryote cells normally synthesise opal suppressor tRNAs. The function of these is not clear and they usually do not prevent normal termination of protein synthesis at an opal codon. (18 Nov 1997) |
| T-lymphocytes, suppressor-effector | Subpopulation of CD8+ T-lymphocytes which suppress antibody production or inhibit cellular immune responses. Suppressor-effector cells execute the message received from suppressor-inducer cells (T-lymphocytes, suppressor-inducer). (12 Dec 1998) |
| T-lymphocytes, suppressor-inducer | Subpopulation of CD4+ lymphocytes which induce CD8+ suppressor T-cells (T-lymphocytes, suppressor-effector) to suppress antibody production by B-cells. They also stimulate other cellular immune responses. (12 Dec 1998) |
| T suppressor cell | <haematology, immunology> Set of T lymphocytes (usually CD8) specifically involved in suppressing B-cell differentiation into antibody secreting cells. There may also be T suppresors of T-cell functions. (18 Nov 1997) |
| t-suppressor cell | A type of immune cells, also called t8 cells, these cells close down the immune response after it has destroyed invading organisms. T8 cells are sensitive to high concentrations of circulating lymphokine hormones and release their own lymphokines after an immune response has achieved its goal, signalling all other participants to cease their attack. Some memory B-cells remain to ward off a repeat attack by the invading organism. (12 Dec 1998) |
| tumour suppressor | <molecular biology, oncology> A gene that encodes a product that normally negatively regulates the cell cycle and that must be mutated or otherwise inactivated before a cell can proceed to rapid division. Examples: p53, RB retinoblastoma), WT 1 (Wilm's tumour), DCC (deleted in colonic carcinoma), NF 1 (neurofibrosarcoma) and APC adenomatous polyposis coli). (18 Nov 1997) |
| acetoacetyl-acyl carrier protein synthase | <enzyme> E coli enzyme, that catalyses condensation of malonyl-acyl carrier protein plus acetyl-acyl carrier protein; not inhibited by cerulenin Registry number: EC 2.3.1.- Synonym: acetoacetyl-acp synthase (26 Jun 1999) |
| acid soluble spore protein | <molecular biology> A DNA binding protein in the spores of some bacteria, thought to stabilise the DNA in an A configuration, so protecting it from cleavage by enzymes or UV light. (18 Nov 1997) |
| acute-phase protein | <haematology> These plasma proteins (in addition to fibrinogen) increase 25% or more in response to inflammation and injury are under direct control of interleukin-6 (IL-6) (hepatocyte-stimulating factor). Other proteins which increase are ceruloplasmin, C3 and C4 which increase 50% or more; alpha-1 acid glycoprotein, alpha-1 antitrypsin, haptoglobin and fibrinogen (the major determinant of viscosity 1 ) which increase two- to fourfold; C-reactive protein (CRP) and serum amyloid A which increase several hundred-fold. Despite long-held clinical opinion to the contrary, available data indicate that neither ESR nor measurement of specific acute-phase reactants are useful in excluding underlying infection or inflammation regardless of the pretest probability. These proteins are secreted into the blood in increased or decreased quantities by hepatocytes in response to trauma, inflammation, or disease. They can serve as inhibitors or mediators of the inflammatory processes. Certain acute-phase proteins have been used to diagnose and follow the course of diseases or as tumour markers. See also: amyloid, c-reactive protein, erythrocyte sedimentation rate, viscosity. (25 Jun 1999) |
| acyl-(acyl-carrier-protein)-phospholipid acyltransferase | <enzyme> Catalyses the formation of phosphatidylethanolamine from acyl-acyl carrier protein and 2-acyl-sn-glycero-3-phosphoethanolamine Registry number: EC 2.3.1.40 Synonym: 2-acyl-gpe acyltransferase, 2-acylglycerophosphoethanolamine acyltransferase (26 Jun 1999) |